Hans Edgar Bishop - 23 Feb 2022 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Heather Turner, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
23 Feb 2022
Net transactions value
+$99,343
Form type
4
Filing time
25 Feb 2022, 15:05:49 UTC
Previous filing
23 Jun 2021
Next filing
21 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Options Exercise $99,343 +993,428 +28% $0.1000* 4,540,234 23 Feb 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Options Exercise $0 -993,428 -85% $0.000000 169,610 23 Feb 2022 Common Stock 993,428 $0.1000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.